The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083
Role of iron in carcinogenesis: cancer as a ferrotoxic disease
Toyokuni, S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2008.01001.x · Cited by 552
Research works printed but not linked: 69
- Ludwig, 2004, The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients, Eur J Cancer, 40, 2293, 10.1016/j.ejca.2004.06.019 · DOI · Paper page
- Beale, 2005, The prevalence of iron deficiency among patients presenting with colorectal cancer, Colorectal Dis, 7, 398, 10.1111/j.1463-1318.2005.00789.x · doi:10.1111/j.1463-1318.2005.00789.x
- Kuvibidila, 2004, Serum ferritin levels and transferrin saturation in men with prostate cancer, J Natl Med Assoc, 96, 641
- Krayenbuehl, 2011, Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration, Blood, 118, 3222, 10.1182/blood-2011-04-346304 · DOI · Paper page
- Aapro, 2008, September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents, Oncologist, 13, 33, 10.1634/theoncologist.13-S3-33 · DOI · Paper page
- Bokemeyer, 2007, EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update, Eur J Cancer, 43, 258, 10.1016/j.ejca.2006.10.014 · DOI · Paper page
- National Comprehensive Cancer Network Inc, 2012, NCCN Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia—v.2
- Rizzo, 2010, American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer, Blood, 116, 4045, 10.1182/blood-2010-08-300541 · DOI · Paper page
- Auerbach, 2004, Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial, J Clin Oncol, 22, 1301, 10.1200/JCO.2004.08.119 · DOI · Paper page
- Auerbach, 2010, Darbepoetin alfa 300 or 500 ug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia, Am J Hematol, 85, 655, 10.1002/ajh.21779 · DOI
- Bastit, 2008, Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia, J Clin Oncol, 26, 1611, 10.1200/JCO.2006.10.4620 · DOI · Paper page
- Hedenus, 2007, Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study, Leukemia, 21, 627, 10.1038/sj.leu.2404562 · DOI · Paper page
- Henry, 2007, Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy, Oncologist, 12, 231, 10.1634/theoncologist.12-2-231 · DOI · Paper page
- Pedrazzoli, 2008, Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha, J Clin Oncol, 26, 1619, 10.1200/JCO.2007.12.2051 · DOI · Paper page
- Dangsuwan, 2010, Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy, Gynecol Oncol, 116, 522, 10.1016/j.ygyno.2009.12.004 · DOI
- Kim, 2007, Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy, Gynecol Oncol, 105, 199, 10.1016/j.ygyno.2006.11.014 · DOI
- Steinmetz, 2010, A new concept for the differential diagnosis and therapy of anaemia in cancer patients, Support Care Cancer, 19, 261, 10.1007/s00520-010-0812-2 · DOI
- Beguin, 2009, A prospective observational study exploring the impact of iron status on response to darbepoetin alfa in patients with chemotherapy induced anemia, Blood, 114, 10.1182/blood.V114.22.2007.2007 · doi:10.1182/blood.v114.22.2007.2007
- Ludwig, 2011, High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status, Haematologica, 96
- Caro, 2001, Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review, Cancer, 91, 2214, 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P · DOI · Paper page
- Nissenson, 2005, Economic burden of anemia in an insured population, J Manag Care Pharm, 11, 565, 10.18553/jmcp.2005.11.7.565 · DOI
- Crawford, 2002, Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy, Cancer, 95, 888, 10.1002/cncr.10763 · DOI · Paper page
- Grotto, 2008, Anaemia of cancer: an overview of mechanisms involved in its pathogenesis, Med Oncol, 25, 12, 10.1007/s12032-007-9000-8 · DOI
- Fillet, 1989, Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation, Blood, 74, 844, 10.1182/blood.V74.2.844.844 · DOI
- Van Wyck, 2004, Labile iron in parenteral iron formulations: a quantitative and comparative study, Nephrol Dial Transplant, 19, 561, 10.1093/ndt/gfg579 · DOI
- Brugnara, 1993, Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects, Blood, 81, 956, 10.1182/blood.V81.4.956.956 · DOI
- Weiss, 2009, Iron metabolism in the anemia of chronic disease, Biochim Biophys Acta, 1790, 682, 10.1016/j.bbagen.2008.08.006 · DOI · Paper page
- Groopman, 1999, Chemotherapy-induced anemia in adults: incidence and treatment, J Natl Cancer Inst, 91, 1616, 10.1093/jnci/91.19.1616 · DOI · Paper page
- Tas, 2002, Anemia in oncology practice: relation to diseases and their therapies, Am J Clin Oncol, 25, 371, 10.1097/00000421-200208000-00011 · DOI
- Untch, 2009, Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer, J Clin Oncol, 27, 2938, 10.1200/JCO.2008.20.3133 · DOI
- Wish, 2006, Assessing iron status: beyond serum ferritin and transferrin saturation, Clin J Am Soc Nephrol, 1, S4, 10.2215/CJN.01490506 · DOI · Paper page
- Beguin, 2002, Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients, Haematologica, 87, 1209
- Thomas, 2006, The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy, Med Oncol, 23, 23, 10.1385/MO:23:1:23 · DOI
- Ludwig, 2010, High prevalence of iron deficiency in patients with various hematological and malignant diseases: a single center study in 1989 sequential patients, Haematologica, 95
- Vamvakas, 2009, Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention, Blood, 113, 3406, 10.1182/blood-2008-10-167643 · DOI · Paper page
- Marik, 2008, Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature, Crit Care Med, 36, 2667, 10.1097/CCM.0b013e3181844677 · DOI · Paper page
- Thomson, 2009, Patient blood management—a new paradigm for transfusion medicine?, ISBT Science Series, 4, 423, 10.1111/j.1751-2824.2009.01251.x · DOI
- Rawn, 2008, The silent risks of blood transfusion, Curr Opin Anaesthesiol, 21, 664, 10.1097/ACO.0b013e32830f1fd1 · DOI
- Amato, 1998, Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors, Dis Colon Rectum, 41, 570, 10.1007/BF02235262 · DOI
- Bohlius, 2009, Erythropoietin or darbepoetin for patients with cancer—meta-analysis based on individual patient data, Cochrane Database Syst Rev, 10.1002/14651858.CD007303.pub2 · DOI
- Gabrilove, 2001, Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing, J Clin Oncol, 19, 2875, 10.1200/JCO.2001.19.11.2875 · DOI · Paper page
- Littlewood, 2001, Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial, J Clin Oncol, 19, 2865, 10.1200/JCO.2001.19.11.2865 · DOI · Paper page
- Ludwig, 2009, Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study, Eur J Cancer, 45, 1603, 10.1016/j.ejca.2009.02.003 · DOI
- Macdougall, 1999, Strategies for iron supplementation: oral versus intravenous, Kidney Int Suppl, 69, S61, 10.1046/j.1523-1755.1999.055Suppl.69061.x · DOI · Paper page
- Steensma, 2011, Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia, J Clin Oncol, 29, 97, 10.1200/JCO.2010.30.3644 · DOI
- Gafter-Gvili, 2010, Intravenous iron supplementation for the treatment of cancer-related anemia—systematic review and meta-analysis, Blood, 116, 10.1182/blood.V116.21.4249.4249 · doi:10.1182/blood.v116.21.4249.4249
- Petrelli, 2012, Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials, J Cancer Res Clin Oncol, 138, 179, 10.1007/s00432-011-1072-3 · DOI
- Steensma, 2011, Reply to M. Aapro et al, J Clin Oncol, 29, e527, 10.1200/JCO.2011.35.4597 · doi:10.1200/jco.2011.35.4597
- Aapro, 2011, Too-low iron doses and too many dropouts in negative iron trial?, J Clin Oncol, 29, e525, 10.1200/JCO.2011.35.3219 · doi:10.1200/jco.2011.35.3219
- Steensma, 2011, The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.9031 · DOI
- Hedenus, 2008, Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy, J Clin Pharm Ther, 33, 365, 10.1111/j.1365-2710.2008.00924.x · DOI
- Steinmetz, 2011, Ferric carboxymaltose for the correction of cancer- and chemotherapy-associated anemia in clinical practice, Haematologica, 96
- Evstatiev, 2011, FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease, Gastroenterology, 141, 846, 10.1053/j.gastro.2011.06.005 · DOI · Paper page
- Kulnigg, 2008, A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial, Am J Gastroenterol, 103, 1182, 10.1111/j.1572-0241.2007.01744.x · DOI · Paper page
- Bailie, 2011, Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America, Drug Res, 61, 267
- Bailie, 2005, Hypersensitivity reactions and deaths associated with intravenous iron preparations, Nephrol Dial Transplant, 20, 1443, 10.1093/ndt/gfh820 · DOI · Paper page
- Chertow, 2006, Update on adverse drug events associated with parenteral iron, Nephrol Dial Transplant, 21, 378, 10.1093/ndt/gfi253 · DOI · Paper page
- Rottembourg, 2011, Do two intravenous iron sucrose preparations have the same efficacy?, Nephrol Dial Transplant, 26, 3262, 10.1093/ndt/gfr024 · DOI
- Schellekens, 2011, The therapeutic equivalence of complex drugs, Regul Toxicol Pharmacol, 59, 176, 10.1016/j.yrtph.2010.09.021 · DOI
- Aronoff, 2004, Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens, Kidney Int, 66, 1193, 10.1111/j.1523-1755.2004.00872.x · DOI
- Zhang, 2008, Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest, J Biol Chem, 283, 33911, 10.1074/jbc.M806432200 · DOI
- Baliga, 1998, In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity, Kidney Int, 53, 394, 10.1046/j.1523-1755.1998.00767.x · DOI · Paper page
- Minotti, 2004, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol Rev, 56, 185, 10.1124/pr.56.2.6 · DOI · Paper page
- Hasinoff, 2008, Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib, Mol Pharmacol, 74, 1722, 10.1124/mol.108.050104 · DOI
- Kamba, 2007, Mechanisms of adverse effects of anti-VEGF therapy for cancer, Br J Cancer, 96, 1788, 10.1038/sj.bjc.6603813 · DOI · Paper page
- Bergeron, 1985, Influence of iron on in vivo proliferation and lethality of L1210 cells, J Nutr, 115, 369, 10.1093/jn/115.3.369 · DOI
- Carthew, 1997, Iron promotes DEN initiated GST-P foci in rat liver, Carcinogenesis, 18, 599, 10.1093/carcin/18.3.599 · DOI
- Auerbach, 2009, What is the right balance between iron and erythropoiesis stimulating agents in chemotherapy induced anemia?, Eur J Clin Med Oncol, 1, 7
- Beguin, 2008, Darbepoetin-alfa and i.v. iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter trial, Blood, 112, 10.1182/blood.V112.11.54.54 · doi:10.1182/blood.v112.11.54.54
Cited by
Iron deficiency anaemia: pathophysiology, assessment, practical management
Kumar, A., Sharma, E., Marley, A., Samaan, M. A., & Brookes, M. J. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000759 · Cited by 344
Masson, N., & Ratcliffe, P. J. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-3 · Cited by 298
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx758 · Cited by 288
Self-citationLudwig, H., Müldür, E., Endler, G., & Hübl, W. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt118 · Cited by 259
Self-citationIron in the Tumor Microenvironment-Connecting the Dots
Pfeifhofer-Obermair, C., Tymoszuk, P., Petzer, V., Weiss, G., & Nairz, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00549 · Cited by 151
Metadata
- Authors
- Aapro, M., Österborg, A., Gascón, P., Ludwig, H., & Beguin, Y.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 23
- Issue
- 8
- Pages
- 1954-1962
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2123275842
- Cited by
- 196
- References
- 3
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2668 d)
- Funders
- Vifor Pharma Ltd
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. https://app.cochat.ai/papers/10.1093/annonc/mds112
- The paper
- Aapro, M., Österborg, A., Gascón, P., Ludwig, H., & Beguin, Y. (2012). Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Annals of Oncology. https://doi.org/10.1093/annonc/mds112
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.